SystHERs

An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer

Objective

This is a multicenter, prospective, observational study designed to follow patients with HER2 positive metastatic brease cancer in the United States.  Initial diagnosis must be within 6 months of diagnosis.  Treatment information is collected every 90 days for approximately 36 months. Patient questionnaire also every 90 days either on site, internet or mail.

IRB Protocol Number

ML 28257

Principal Investigator(s)

Brock Whittenberger, MD

Sponsor(s)

Roche Genentech

Contact

Tauna Jeffery, RN at 406-435-7484
or tjeffery@billingsclinic.org